PerkinElmer Inc Stock News

PerkinElmer, Inc. (NYSE:PKI ) Q4 2022 Earnings Conference Call February 14, 2023 8:00 AM ET Company Participants Steve Willoughby - SVP, IR Prahlad Singh - President and CEO Max Krakowiak - SVP and CF

PerkinElmer (PKI) delivered earnings and revenue surprises of 2.41% and 1.97%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the fourth quarter and full year end

PerkinElmer continues to offer long-term upside potential with its management of capital and acquisitions. The economic value of its transactions has created a healthy return on investment over the ti

Mr. Rongen appointed as CEO and member of the Board bringing 30 years of executive leadership experience and expertise across a number of therapeutic areas Bolstered expertise on Board of Directors wi

WALLINGFORD, Conn.--( BUSINESS WIRE )--Amphenol Corporation (NYSE: APH) today announced that Prahlad Singh, PhD has been appointed to Amphenol's board of directors. With his appointment, the size of t

PerkinElmer, Inc. (NYSE:PKI ) 41st Annual J.P. Morgan Healthcare Conference Call January 10, 2023 11:15 AM ET Company Participants Prahlad Singh - President and Chief Executive Officer Conference Call

PerkinElmer (PKI) continues to gain from a solid product portfolio despite forex woes.

The Zacks Instruments - Scientific industry participants like Mettler-Toledo (MTD), PerkinElmer (PKI) and Waters (WAT) are gaining from strong life science, pharmaceutical and academic end-market dema

PerkinElmer (PKI) reported earnings 30 days ago. What's next for the stock?

PerkinElmer's (PKI) latest launch is expected to help researchers expand options to measure viral titers, unlike ELISA and other wash-based systems.

PerkinElmer's (PKI) EONIS SCID-SMA assay kit is expected to enable early SMA and SCID screening in newborns following the FDA's approval.

WALTHAM, Mass.

PerkinElmer's (PKI) third-quarter results benefit from the solid performance of the Discover & Analytics Solutions business, which was more than offset by lower COVID-related sales.

PerkinElmer, Inc. (NYSE:PKI ) Q3 2022 Earnings Conference Call November 8, 2022 8:00 AM ET Company Participants Steve Willoughby - Senior Vice President, Investor Relations Prahlad Singh - President a